Literature DB >> 23993960

Transglutaminase 2 as a novel activator of LRP6/β-catenin signaling.

S Deasey1, D Nurminsky, S Shanmugasundaram, F Lima, M Nurminskaya.   

Abstract

The β-catenin signaling axis is critical for normal embryonic development and tissue homeostasis in adults. We have previously shown that extracellular enzyme transglutaminase 2 (TG2) activates β-catenin signaling in vascular smooth muscle cells (VSMCs). In this study, we provide several lines of evidence that TG2 functions as an activating ligand of the LRP5/6 receptors. Specifically, we show that TG2 synergizes with LRP6 in the activation of β-catenin-dependent gene expression in Cos-7 cells. Interfering with the LRP5/6 receptors attenuates TG2-induced activation of β-catenin in Cos-7 cells. Further, we show that TG2 binds directly to the extracellular domain of LRP6, which is also able to act as a substrate for TG2-mediated protein cross-linking. Furthermore, inhibitors of TG2 protein cross-linking quench the observed TG2-induced β-catenin activation, implicating protein cross-linking as a novel regulatory mechanism for this pathway. Together, our findings identify and characterize a new activating ligand of the LRP5/6 receptors and uncover a novel activity of TG2 as an agonist of β-catenin signaling, contributing to the understanding of diverse developmental events and pathological conditions in which transglutaminase and β-catenin signaling are implicated.
© 2013.

Entities:  

Keywords:  APC; Adenomatosis Polyposis Coli; E. coli; ECM; Escherichia coli; Extracellular matrix; Frizzled; Fzd; GSK3; Glycogen Synthase Kinase 3; Guinea pig liver TG2; Human TG2; LRP5 or LRP6; LRP5/6; MEFs; Mouse embryonic fibroblasts; TG2; TGases; Tissue transglutaminase; Transglutaminases; Transglutaminsase 2; VSMCs; Vascular smooth muscle cells; gpTG2; hTG2; ß-catenin

Mesh:

Substances:

Year:  2013        PMID: 23993960      PMCID: PMC3881002          DOI: 10.1016/j.cellsig.2013.08.016

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  49 in total

Review 1.  Wnt signaling: a key regulator of bone mass.

Authors:  Roland Baron; Georges Rawadi; Sergio Roman-Roman
Journal:  Curr Top Dev Biol       Date:  2006       Impact factor: 4.897

2.  Implications of tissue transglutaminase expression in malignant melanoma.

Authors:  Jansina Y Fok; Suhendan Ekmekcioglu; Kapil Mehta
Journal:  Mol Cancer Ther       Date:  2006-06       Impact factor: 6.261

3.  Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF.

Authors:  Rima Dardik; Aida Inbal
Journal:  Exp Cell Res       Date:  2006-06-07       Impact factor: 3.905

Review 4.  The WNT/Beta-catenin pathway in melanoma.

Authors:  Lionel Larue; Véronique Delmas
Journal:  Front Biosci       Date:  2006-01-01

Review 5.  Function and biological roles of the Dickkopf family of Wnt modulators.

Authors:  C Niehrs
Journal:  Oncogene       Date:  2006-12-04       Impact factor: 9.867

6.  LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.

Authors:  Mikhail V Semenov; Xi He
Journal:  J Biol Chem       Date:  2006-10-19       Impact factor: 5.157

Review 7.  Multiplicity of the interactions of Wnt proteins and their receptors.

Authors:  Akira Kikuchi; Hideki Yamamoto; Shosei Kishida
Journal:  Cell Signal       Date:  2006-11-16       Impact factor: 4.315

Review 8.  Roles and regulation of Wnt signaling and beta-catenin in prostate cancer.

Authors:  Meletios Verras; Zijie Sun
Journal:  Cancer Lett       Date:  2005-07-14       Impact factor: 8.679

9.  An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth.

Authors:  Naoaki Fujii; Liang You; Zhidong Xu; Kazutsugu Uematsu; Jufang Shan; Biao He; Iwao Mikami; Lillian R Edmondson; Geoffrey Neale; Jie Zheng; R Kiplin Guy; David M Jablons
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

10.  Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.

Authors:  Debra L Ellies; Beth Viviano; John McCarthy; Jean-Philippe Rey; Nobue Itasaki; Scott Saunders; Robb Krumlauf
Journal:  J Bone Miner Res       Date:  2006-11       Impact factor: 6.741

View more
  6 in total

Review 1.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

2.  Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche.

Authors:  Salvatore Condello; Livia Sima; Cristina Ivan; Horacio Cardenas; Gary Schiltz; Rama K Mishra; Daniela Matei
Journal:  Cancer Res       Date:  2018-03-06       Impact factor: 12.701

3.  Transglutaminases factor XIII-A and TG2 regulate resorption, adipogenesis and plasma fibronectin homeostasis in bone and bone marrow.

Authors:  Aisha Mousa; Cui Cui; Aimei Song; Vamsee D Myneni; Huifang Sun; Jin Jin Li; Monzur Murshed; Gerry Melino; Mari T Kaartinen
Journal:  Cell Death Differ       Date:  2017-04-07       Impact factor: 15.828

4.  Transglutaminase 2 promotes PDGF-mediated activation of PDGFR/Akt1 and β-catenin signaling in vascular smooth muscle cells and supports neointima formation.

Authors:  Maria Nurminskaya; Kelly E Beazley; Elizabeth P Smith; Alexey M Belkin
Journal:  J Vasc Res       Date:  2015-01-22       Impact factor: 1.934

Review 5.  The Outside-In Journey of Tissue Transglutaminase in Cancer.

Authors:  Livia Elena Sima; Daniela Matei; Salvatore Condello
Journal:  Cells       Date:  2022-05-29       Impact factor: 7.666

6.  Biochemical Characterization of Medaka (Oryzias latipes) Transglutaminases, OlTGK1 and OlTGK2, as Orthologues of Human Keratinocyte-Type Transglutaminase.

Authors:  Ayaka Kikuta; Eri Furukawa; Ryota Ogawa; Natsuki Suganuma; Mai Saitoh; Toshiyuki Nishimaki; Takafumi Katsumura; Hiroki Oota; Tadafumi Kawamoto; Hideki Tatsukawa; Hisashi Hashimoto; Kiyotaka Hitomi
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.